用三种方法筛选携带ALK基因融合/倒位的晚期或复发NSCLC患者,免疫荧光原位杂交(flourescence in situ hybridization, FISH)显示阳性者给予克唑替尼口服,250 mg,2次/d。评价客观有效率(objective response rate, ORR)、无进展生存期(progression-free survival, PFS)及安全性。. Here, ALK is linked to non-small cell lung carcinoma.